• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Benefits of Improved Vehicle of Dermatological Steroidal Treatments


Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.

Linda F. Stein Gold, MD: As you mentioned, patients especially…they want to use a steroid, they might use it on larger body surface areas. We do have and we talked about…the fact that we now have more sophisticated…designer vehicles…where we get more of [those] depot effects, where we don’t see the drug really transitioning all the way through the epidermis but more staying at the site of action as opposed to just going rapidly through and into the systemic circulation. Do either of you find value in that?

Darren West, MPAS, PA-C: [A]bsolutely. But…that’s why…today we’re more comfortable writing [prescriptions for] steroids as well as they’re just better…. The vehicle will matter...in many instances. Unfortunately, I can’t get great products for all my patients, but those I can get them to, I love those newer products. And yes, it’s more effective, it’s safer. And I know I worry much less about any of those secondary [adverse] effects because of it.

Linda F. Stein Gold, MD: Jayme, do you agree?

Jayme M. Heim, MSN, FNP-BC: I agree. They’re using it for a shorter duration of time. They’re much more effective. And [there is] the fact that they’re actually more cosmetically elegant for the patients—[for] patients to not have grease all over everything, all over their clothing or else…they have a screen that’s just sitting on their skin the whole time, and it’s really not doing what it really effectively needs to do. So, our new agents…are nice. But like Darren said…not all our patients get access to that type of medication.

Linda F. Stein Gold, MD: I agree with you both…. [W]hen somebody comes in and they have an acute problem, they have contact dermatitis, I know it’s going to go away no matter what I give them; I’m often going to pick a generic that’s going to be cheap and easy. It’s those patients who have those chronic diseases where I know that they’re going to have to put on a medication in bursts over the course of time. That’s one [instance where] I’m a little more selective and really looking for a drug with more of a designer vehicle that I know potentially is safer for the long term, more cosmetically [elegant]. I might have to fight a little bit more with insurance. But I think for a chronic condition…patients appreciate it a little bit more.

Transcript is AI-generated and edited for clarity and readability.

Related Videos
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 3 - featuring 2 panelists in, "Navigating Treatment Challenges: Addressing Negative Responses and Determining the Next Course of Action "
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 2 - "Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management" - 2 KOLs in this video.
Video 2 - "Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis"
Video 1 - "Creating a Connection: First Appointment Insights and Critical Inquiries Providers Should Make"
Video 1 - "Insights for Clinicians: Leveraging Real-World Data for Informed Practice"
© 2024 MJH Life Sciences

All rights reserved.